Received Feb 14, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (JANSSEN)) | JANSSEN | UNK | — | — |
Guillain-Barre syndrome; This spontaneous report received from a patient concerned a male patient of unspecified age. Received via J and J managed social media. The patient's height and weight were not reported. Age at time of vaccination was unknown. No past medical history, concurrent conditions or pre-existing medical conditions were reported. The patient received janssen covid-19 vaccine (suspension for injection, intramuscular, batch number not reported) dose, frequency and therapy dates not reported, additional dosage information included: dose series 1, for covid-19 prophylaxis. The batch number was not reported. The company is unable to perform follow up to request batch/lot numbers. No concomitant medications were reported. On an unspecified date, the patient experienced guillain-barre syndrome. (dose series 1) Now the patient have very weak muscles and now paralyzed. The action taken with janssen covid-19 vaccine was not applicable. The outcome of guillain-barre syndrome was not reported. This report was serious (other medically important condition).; Sender's Comments: V0: janssen covid-19 vaccine -Guillain-Barre syndrome. This event(s) is labeled per RA and is therefore considered potentially related.